Tagamet HB/Mylanta comparative ads struck down by U.S. court of appeals.
This article was originally published in The Tan Sheet
Executive Summary
TAGAMET HB COMPARATIVE ADS VERSUS MYLANTA REJECTED by a federal appeals court on Jan. 30. The decision by the U.S. Court of Appeals for the Second Circuit affirms an earlier permanent injunction judgment by federal Judge Harold Baer, whose Dec. 6 order enjoined SmithKline Beecham from using, in any advertisement or promotional material, the claim: "Doctors prefer [Tagamet HB to Mylanta] for patients suffering from frequent heartburn."